| OncoC4
Summary
OncoC4 closed a nearly $50 million Series B financing round led by GBA Fund with participation from existing investors and co-founders. The clinical-stage biotechnology company plans to use the proceeds to advance its pipeline programs. The company focuses on novel biologics for cancer and neurodegenerative disease, with assets targeting oncology and immunological diseases. This financing strengthens OncoC4’s ability to continue clinical development and expand business development efforts.
Funding
Amount
$50.0M
Total raised
Date
October 2, 2025
Announcement date
Investors
Kaitai Capital, HM Capital
Lead investors
Company
-
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected